Movetis Seeking up to 112.4 Million Euros in IPO

Fri, 20 Nov 2009 12:00:00 AM GMT

FDA Approves Intravenous Formulation Of Pfizer Inc.'s Revatio(R) (Sildenafil) For The Treatment Of Pulmonary Arterial Hypertension

Fri, 20 Nov 2009 12:00:00 AM GMT

Covidien Says FDA Extends Review of Opiod Pain Drug

Fri, 20 Nov 2009 12:00:00 AM GMT

Roche's Actemra Successful in Arthritis Study; Meets Primary Endpoint in Phase III Study

Fri, 20 Nov 2009 12:00:00 AM GMT

FDA Advisory Committee Finds Data Support the Claim That Pfizer Inc.'s SPIRIVA(R) HandiHaler(R) Reduces COPD Exacerbations

Fri, 20 Nov 2009 12:00:00 AM GMT

EU Panel Blocks Merck KGaA's Erbitux in Lung Cancer

Fri, 20 Nov 2009 12:00:00 AM GMT

Ranbaxy Laboratories Recalls Skin Infection Drug, Sotret in the U.S.

Fri, 20 Nov 2009 12:00:00 AM GMT

Business-Standard.com -- Indias leading drug maker Ranbaxy has initiated a voluntary recall of 4,348 cartons of its skin infection drug Sotret (isotretinoin) in the United States. The entire lot pertains to a single batch of tablets which were found to be out of specification.

Antigenics Inc. (New York) Cancer Vaccine Gets Negative EU Panel Vote

Fri, 20 Nov 2009 12:00:00 AM GMT

Merck & Co., Inc. Receives CHMP Positive Opinion for New Fertility Treatment, ELONVA(R)

Fri, 20 Nov 2009 12:00:00 AM GMT

Dendreon Corporation Receives FDA Acknowledgement of Complete Response, PDUFA Date Assigned as May 1, 2010

Fri, 20 Nov 2009 12:00:00 AM GMT

SEATTLE, Nov 20, 2009 /PRNewswire-FirstCall via COMTEX/ -- Dendreon Corporation (Nasdaq: DNDN) today announced that the U.S. Food and Drug Administration (FDA) provided written acknowledgement that the Company's amended Biologics License Application (BLA) for PROVENGE(R) (sipuleucel-T) is a complete response. The FDA has assigned a Prescription Drug User Fee Act (PDUFA) date of May 1, 2010, by which...

Cell Therapeutics, Inc. Wins Federal Appeal to Pursue $22.8 Million Claim Against

Fri, 20 Nov 2009 12:00:00 AM GMT

Procter & Gamble Repurchasing Shares, Quiet on Potential Deals

Fri, 20 Nov 2009 12:00:00 AM GMT

Pfizer Inc. Executive: In Talks To Expand Licensing Pact With Aurobindo Pharma

Fri, 20 Nov 2009 12:00:00 AM GMT

GlaxoSmithKline, Merck & Co., Inc. Developing Drugs for Kala Azar, Disease Transmitted by Sandflies

Fri, 20 Nov 2009 12:00:00 AM GMT

Sucampo Pharma Europe Receives Marketing Authorization for Amitiza(R) in Switzerland for Treatment of Chronic Idiopathic Constipation

Fri, 20 Nov 2009 12:00:00 AM GMT

FDA Extends NDA Review for Neuromed Pharmaceuticals's Exalgo(TM) Extended-Release Tablets

Fri, 20 Nov 2009 12:00:00 AM GMT

CAMBRIDGE, Mass. & VANCOUVER, British Columbia--(BUSINESS WIRE)--CombinatoRx, Incorporated (NASDAQ: CRXX) and Neuromed Pharmaceuticals Inc., a privately-held biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has issued Neuromed a letter extending its review of the New Drug Application (NDA) for the product candidate Exalgo (hydromorphone HCl) extended-release...

Recordati S.p.A: European Medicines Evaluation Agency Adopts A Positive Opinion For Silodosin (Brands Urorec(R) And Silodyx(R))

Fri, 20 Nov 2009 12:00:00 AM GMT

Pfizer Inc. Receives FDA Approval For Geodon(R) (Ziprasidone HCI) Capsules For The Adjunctive Maintenance Treatment Of Bipolar Disorder In Adults

Fri, 20 Nov 2009 12:00:00 AM GMT

Genta Incorporated's Genasense(R) Given as High-Dose IV Infusion with Chemotherapy Shows Promising Activity in Advanced Melanoma

Fri, 20 Nov 2009 12:00:00 AM GMT

Pozen, Inc. Announces Start of Enrollment For PA32540 Phase 3 Program

Fri, 20 Nov 2009 12:00:00 AM GMT

CHAPEL HILL, N.C.--(BUSINESS WIRE)--POZEN Inc. (NASDAQ: POZN) announced today the start of enrollment for the phase 3 studies for PA32540. PA32540 is a fixed-dose combination of 325 mg of enteric coated aspirin and 40 mg of immediate release omeprazole, under investigation for use in the secondary prevention of heart attacks and strokes in patients at risk for associated gastric ulcers.

Circassia Limited Announces Successful Results From Phase II Clinical Study of ToleroMune(R) Cat Allergy Therapy Study Identifies Optimal Treatment Approach for Late-Stage Development

Fri, 20 Nov 2009 12:00:00 AM GMT

OXFORD, England, November 20 /PRNewswire/ -- Circassia Ltd, a specialty biopharmaceutical company focused on allergy, today announced positive results from a recently completed phase II clinical study of its ToleroMune(R) cat allergy therapy, which successfully identified the optimal dosing regimens to progress into late-stage development. The clinical trial, which was the first of its kind...

Stem Cell Therapeutics Announces Positive Review by Data Safety and Monitoring Board for the Phase IIb Stroke Trial

Fri, 20 Nov 2009 12:00:00 AM GMT

Moberg Derma Reports Positive Phase II Results For K201 Against Atopic Eczema

Fri, 20 Nov 2009 12:00:00 AM GMT

Ligand Pharmaceuticals Inc. Presents New Preclinical Data on its Lead SARM Molecule LGD-4033 at the Annual Meeting

Fri, 20 Nov 2009 12:00:00 AM GMT

SAN DIEGO--(BUSINESS WIRE)--Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today announced that data from a preclinical study on its selective androgen receptor modulator (SARM) LGD-4033 was featured in a poster presentation at the 62nd Annual Meeting of the Gerontology Society of America in Atlanta. LGD-4033 exhibited desirable in vivo efficacy on skeletal muscle and bone measurements in animal...

Inovio Biomedical Corporation Universal Flu Vaccines Demonstrate Broadly Protective Immune Responses Against Multiple Seasonal & Pandemic Influenza Viruses in Pre-Clinical Studies

Fri, 20 Nov 2009 12:00:00 AM GMT

SAN DIEGO--(BUSINESS WIRE)--Inovio Biomedical Corporation (NYSE Amex:INO), a leader in DNA vaccine design, development and delivery, announced today that a combination of its synthetic consensus H1N1, H2N2, H3N2, and H5N1 influenza vaccine candidates achieved protective antibody responses against several different influenza sub-types and strains in ferrets. In addition, ferrets immunized with Inovio...

IMPAX Laboratories, Inc. Drives Stronger Performance with Business Analytics

Fri, 20 Nov 2009 12:00:00 AM GMT

ARMONK, N.Y., Nov. 20 /PRNewswire-FirstCall/ -- IBM announced today that Impax Laboratories, Inc. , a technology-based specialty pharmaceutical company, is using IBM business analytics technology to gain stronger insights into their business and better predict risks and market opportunities.

(Logo: http://www.newscom.com/cgi-bin/prnh/20090416/IBMLOGO )

In such a highly...

Karolinska Development AB and Start Landmark Co-Investment Fund for Life Science Innovation

Fri, 20 Nov 2009 12:00:00 AM GMT

STOCKHOLM, November 20 /PRNewswire/ -- Karolinska Development AB today announced that the European Investment Fund (EIF) has entered into a co-investment agreement with the company. The co-investment fund will be managed by Karolinska Development and used to invest in the company's portfolio of early-stage pharmaceutical and medical technology companies. EIF has agreed to invest 26.7 M Euros...

Arcadia Biosciences, Inc. and Announce Strategic Alliance to Develop and Market Nitrogen Use Efficient Wheat

Fri, 20 Nov 2009 12:00:00 AM GMT

DAVIS, Calif. & PARIS--(BUSINESS WIRE)--Arcadia Biosciences, Inc., an agricultural technology company focused on developing technologies and products that benefit the environment and human health, and Vilmorin, the worlds fourth-largest seed company and the global leader in wheat genetics and seed, today announced that they have reached an agreement for the development and commercialization of Nitrogen...

KineMed, Inc. Receives an Investigator-Initiated Study Grant From Daiichi Sankyo Co Ltd. to Further Explore Mechanism(s) of Action Associated with Welchol(R) (colesevelam HCl) in Type 2 Diabetes Mellitus

Fri, 20 Nov 2009 12:00:00 AM GMT

EMERYVILLE, Calif.--(BUSINESS WIRE)--KineMed, Inc., a translational and personalized medicine development company, announced today that the company has received an investigator initiated study grant from Daiichi Sankyo, Inc. to conduct a clinical study designed to better understand and characterize the beneficial effects of Welchol (colesevelam HCl) in patients with Type 2 Diabetes Mellitus (T2DM...

Cambridge-based Raises $1M in Seed Funding

Fri, 20 Nov 2009 12:00:00 AM GMT

CAMBRIDGE, Mass., Nov. 19 /PRNewswire/ -- Ligon Discovery, Inc., which uses proprietary small molecule microarray technology to find drugs against high-value targets, today announced that it has raised $1M in seed financing led by incTANK Ventures. The company will use the capital to complete its initial discovery campaign that will screen over 100 high-value disease protein targets. With...

Warner Chilcott Prices Secondary Equity Offering

Fri, 20 Nov 2009 12:00:00 AM GMT

ARDEE, Ireland, Nov. 19 /PRNewswire/ -- Warner Chilcott plc today announced the pricing of its previously announced secondary offering of 20,000,000 of its ordinary shares at a price to the public of $22.25 per share. The selling shareholders include funds affiliated with Bain Capital Partners, DLJ Merchant Banking, J.P. Morgan Partners (advised by CCMP Capital) and Thomas H. Lee Partners...

KINAXO Biotechnologies Completes Financing Round to Enhance Biomarker Development

Fri, 20 Nov 2009 12:00:00 AM GMT

Martinsried, Germany, November 20, 2009 / b3c newswire / - KINAXO Biotechnologies GmbH announces the completion of a financing round, gaining two new investors in the company, Leifina and Conmit Invest. At the same time KINAXO reports that Jrgen Schumacher has been elected as a new member of the companys advisory board.

KINAXO shareholders Axel Ullrich, Hellmut Kirchner, Manfred Ferber...

Newron Pharmaceuticals Raises CHF7.9m (7.75m USD) In A Private Placement To International Institutional Investors

Fri, 20 Nov 2009 12:00:00 AM GMT

Milan, Italy 20 November 2009 Newron Pharmaceuticals S.p.A. (Newron), a research and development company focused on novel CNS and pain therapies, announced that it has raised gross proceeds of CHF7.9m through a private placement to institutional investors. The private placement was conducted without preferential subscription rights to institutional investors and was managed by Jefferies International...

Sensient Technologies Corporation Announces Private Placement Debt Transaction

Fri, 20 Nov 2009 12:00:00 AM GMT

MILWAUKEE--(BUSINESS WIRE)--Sensient Technologies Corporation (NYSE: SXT) announced today that it has entered into an agreement with a group of financial institutions for the issuance of $110 million in fixed-rate, senior notes. The dollar-denominated debt will have a six-year average life with a final maturity in May 2017. Proceeds from the offering will be used to repay outstanding debt.

Biocryst Pharmaceuticals Announces Pricing of Public Offering of Common Stock

Fri, 20 Nov 2009 12:00:00 AM GMT

BIRMINGHAM, Ala., Nov. 19 /PRNewswire-FirstCall/ -- BioCryst Pharmaceuticals, Inc. today announced the pricing of a public offering of 5,000,000 shares of its common stock at $9.75 per share, resulting in gross proceeds of $48.75 million. All of the shares are being offered by BioCryst pursuant to an effective shelf registration statement previously filed with the Securities and Exchange...

GLG Life Tech Corporation Commences Trading on NASDAQ

Fri, 20 Nov 2009 12:00:00 AM GMT

VANCOUVER, BRITISH COLUMBIA--(Marketwire - November 20, 2009) - GLG Life Tech Corporation (TSX: GLG)(NASDAQ: GLGL) ("GLG" or the "Company"), the vertically integrated leader in the agricultural and industrial development of high quality stevia...

Spherix Announces Results of Annual Shareholders Meeting

Fri, 20 Nov 2009 12:00:00 AM GMT

BETHESDA, Md., Nov. 19 /PRNewswire-FirstCall/ -- Spherix Incorporated , an innovator in biotechnology for diabetes therapy, and a provider of technical and regulatory consulting services to food, supplement, biotechnology and pharmaceutical companies, today announced the results of Tuesday's Annual Meeting of Shareholders.

At the meeting, shareholders of Spherix Incorporated elected...

Annual and Special Shareholders meeting of ZoomMed/Pharmaceutical Contracts Signed for $1,482,500 During Q1-Q2

Fri, 20 Nov 2009 12:00:00 AM GMT

MONTREAL, QUEBEC--(Marketwire - November 20, 2009) - ZoomMed Inc. (TSX VENTURE: ZMD), creator of the ZRx Prescriber, the e-Pic communication network and the ZRx Pharma communication network announced during its shareholders meeting held today 10:00 am, the signing new contracts with pharmaceutical companies...

China Cord Blood Completes Secondary Offering on NYSE

Fri, 20 Nov 2009 12:00:00 AM GMT

ChinaBio Today -- China Cord Blood Corporation listed its ordinary shares on the New York Stock Exchange and, at the same time, completed a secondary offering. The company placed 3.3 million shares at a price of $6.05 for gross proceeds of $20 million. China allows one cord blood collection license for each major area, and China Cord Blood owns the licenses for Beijing and Guangdong. More details...

Omnicare, Inc. Declares Quarterly Cash Dividend

Fri, 20 Nov 2009 12:00:00 AM GMT

COVINGTON, Ky.--(BUSINESS WIRE)--The Board of Directors of Omnicare, Inc. (NYSE:OCR), a leading provider of pharmaceutical care for the elderly, declared today a quarterly cash dividend of 2.25 cents ($0.0225) per share on its common stock. The dividend is payable December 21, 2009 to stockholders of record on December 7, 2009.

Lannett Company, Inc. Reauthorizes Stock Repurchase Program

Fri, 20 Nov 2009 12:00:00 AM GMT

PHILADELPHIA--(BUSINESS WIRE)--Lannett Company, Inc. (NYSE AMEX: LCI) today announced that its Board of Directors has approved a reauthorization of the stock repurchase program. Under the program, the company is authorized to repurchase up to $5 million of Lannetts outstanding common stock from time to time in open market and privately negotiated transactions.

XOMA (US) LLC Receives Determination Letter

Fri, 20 Nov 2009 12:00:00 AM GMT

BERKELEY, Calif., Nov. 19, 2009 (GLOBE NEWSWIRE) -- XOMA Ltd. (Nasdaq:XOMA), a leader in the discovery and development of therapeutic antibodies, announced that it received a letter from the staff of The NASDAQ Stock Market LLC on November 13, 2009 indicating that the NASDAQ staff has concluded that XOMA's previously-announced common share financing completed on September 30, 2009 did not comply with...

EKR Therapeutics, Inc. Named Private Company of the Year By New Jersey Technology Council

Fri, 20 Nov 2009 12:00:00 AM GMT

BEDMINSTER, N.J.--(BUSINESS WIRE)--EKR Therapeutics, Inc., a specialty pharmaceutical company focused on commercializing acute-care hospital products, today announced that it has been named Private Company of the Year by the New Jersey Technology Council (NJTC), a more than 1,200 member non-for-profit organization supporting growth in New Jersey's various technology sectors including health sciences...

WaferGen Biosystems to Introduce New Service for Gene-Expression Profiling Using the SmartChip(TM) Real-Time PCR System

Fri, 20 Nov 2009 12:00:00 AM GMT

FREMONT, Calif., Nov. 19 /PRNewswire-FirstCall/ -- WaferGen Biosystems, Inc. , a leading developer of state-of-the-art genetic analysis systems, today announced a new, innovative service for gene-expression profiling of thousands of genes using the SmartChip(TM) Real-Time PCR System. By taking advantage of the SmartChip Real-Time PCR system, WaferGen will offer universities, pharmaceutical...

Company Profile for Amneal Pharmaceuticals

Fri, 20 Nov 2009 12:00:00 AM GMT

(BUSINESS WIRE)--Amneal Pharmaceuticals LLC, headquartered in Hauppauge, NY is a U.S.-based firm that develops, manufactures and distributes generic pharmaceuticals regulated and approved by the U.S. FDA. Known as Generics New Generation, the company utilizes its newly expanded R&D and manufacturing capabilities to conceive breakthrough developments with lasting impact for a robust product pipeline...

Company Profile for

Fri, 20 Nov 2009 12:00:00 AM GMT

(BUSINESS WIRE)--PreventionGenetics, a market leading biotechnology company located in Marshfield, WI, provides DNA testing for clinical and research and DNA Banking for all individuals. PreventionGenetics offers clinical DNA testing for more than 300 different disorders, making it one of the most comprehensive genetics testing laboratories in the world.

GlaxoSmithKline to Manufacture Flu Treatment Relenza in China

Fri, 20 Nov 2009 12:00:00 AM GMT

ChinaBio Today -- GlaxoSmithKline will begin manufacturing its treatment for flu, Relenza, in China to supply Chinas domestic market. GSK received approval of the drug in September from the SFDA. Relenza, like Tamiflu from Roche, aims at reducing both the severity and the duration of flu symptoms, though some resistance to the drugs seems to be evident. More details...

Formatech, Inc. Release: The New Face of Formatech.com

Fri, 20 Nov 2009 12:00:00 AM GMT

ANDOVER, Mass.--(BUSINESS WIRE)--Formatech, Inc is pleased to announce the launch of their new website. The redesigned site features detailed information about the variety of services Formatech offers, including: product development, lyophilization development, their signature Stability Fingerprinting program and cGMP manufacturing capabilities to support clinical trials, to name a few. The site also...

SaBTO Recommends Use of ProMetic Life Sciences Inc.'s P-Capt(R) Prion Reduction Filter to Protect Children From vCJD Blood Transmission

Fri, 20 Nov 2009 12:00:00 AM GMT

MONTREAL, QUEBEC, CANADA and LILLE, FRANCE--(Marketwire - November 20, 2009) - ProMetic Life Sciences Inc. (TSX: PLI) ("ProMetic") and MacoPharma SA ("MacoPharma") announce that the Advisory Committee on the Safety of Blood, Tissues and Organs ("SaBTO"), an independent Committee that advises the UK Department...

Cellectis BioResearch Launches Cgps(R) CHO-S CEMAX(R) - An Efficient Protein Production Kit

Fri, 20 Nov 2009 12:00:00 AM GMT

Paris, November 4, 2009 - Cellectis bioresearch, a specialist in genomecustomization and a subsidiary of Cellectis S.A. (Alternext: ALCLS), today launchedcGPS CHO-S CEMAX, a kit which enables targeted integration into suspensioncell cultures. By reducing the amount of time required to obtain clones and byimproving production stability, this kit represents an advancement in the production...

Devgen NV Business Update

Fri, 20 Nov 2009 12:00:00 AM GMT

Zwijnaarde, Belgium - November 20, 2009 - Devgen nv (Euronext Brussels; DEVG) issues today a business and financial update for the third quarter 2009.

Operational highlights Q3 2009

Regulatory approval and market launch of Devgen's nematicide in Turkey

Devgen received regulatory approval for its nematicide product Devguard in Turkey for use in four of the most important...

Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights

Fri, 20 Nov 2009 12:00:00 AM GMT

SEATTLE, Nov. 19 /PRNewswire-FirstCall/ -- Omeros Corporation today announced unaudited financial results for the third quarter ended September 30, 2009. For the three months ended September 30, 2009, Omeros reported a net loss of $3.9 million, or $1.34 per share, as compared to a net loss of $7.4 million, or $2.54 per share, for the same period in 2008. For the nine months ended September 30...

RaySearch Laboratories Interim report January 1 ??? September 30, 2009

Fri, 20 Nov 2009 12:00:00 AM GMT

STOCKHOLM, Sweden--(BUSINESS WIRE)--Regulatory News: RaySearch Laboratories (STO:RAYB):

SeraCare, Inc. Reports Fourth Quarter and Fiscal Year 2009 Results

Fri, 20 Nov 2009 12:00:00 AM GMT

MILFORD, Mass.--(BUSINESS WIRE)--SeraCare Life Sciences, Inc. (NASDAQ: SRLS), a global life sciences company providing vital products and services to facilitate the discovery, development and production of human diagnostics and therapeutics, today reported operational and financial results for its fourth quarter and fiscal year ended September 30, 2009.

Frontage Laboratories Expands Management Team

Fri, 20 Nov 2009 12:00:00 AM GMT

EXTON, Pa.--(BUSINESS WIRE)--Frontage, a leading high quality provider of drug development services and preclinical, bioanalytical, analytical, and formulation services to the global biopharmaceutical industry, announces the hire of two key leadership positions and an expansion to the business development team.

PharMerica Names to Its Board of Directors

Fri, 20 Nov 2009 12:00:00 AM GMT

LOUISVILLE, Ky.--(BUSINESS WIRE)--PharMerica Corporation (NYSE: PMC), a national provider of institutional pharmacy and hospital pharmacy management services, announced that it has appointed Geoffrey G. Meyers to the Companys Board of Directors.

Labopharm to Present at Dundee Emerging Growth Summit

Fri, 20 Nov 2009 12:00:00 AM GMT

LAVAL, QC, Nov. 20 /PRNewswire-FirstCall/ - Labopharm Inc. today announced that James R. Howard-Tripp, President & Chief Executive Officer of the Company, will present at the Dundee Emerging Growth Summit at the Design Exchange in Toronto, on Thursday, November 26, 2009 at 2:30 p.m. ET.

About Labopharm Inc.

Labopharm is an emerging leader in optimizing the performance...

Alexza Pharmaceuticals, Inc. to Present at the 21st Annual Piper Jaffray Health Care Conference

Fri, 20 Nov 2009 12:00:00 AM GMT

MOUNTAIN VIEW, Calif., Nov. 19 /PRNewswire-FirstCall/ -- Alexza Pharmaceuticals, Inc. announced today that its corporate presentation will be webcast live during the 21st Annual Piper Jaffray Health Care Conference on Wednesday, December 2, 2009 at 9:00 a.m. Eastern Time. The presentation will be webcast from The New York Palace Hotel in New York and will be presented by Thomas B. King...

ImmuPharma plc CEO Slams Stock Plunge After Drug Trial